We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The J. M. Smucker Company (SJM - Free Report) reported third-quarter fiscal 2019 results, wherein both top and bottom lines beat the Zacks Consensus Estimate and the former improved year over year. Moreover, management reiterated its earnings outlook range, whose mid-point stands above the current consensus mark.
Markedly, the company envisions fiscal 2019 adjusted earnings per share (EPS) in the range of $8.00-$8.20, whose mid-point of $8.10 is well above the current Zacks Consensus Estimate of $8.02. These factors seem to have spurred investors’ optimism in the stock, which gained almost 7% during the pre-market trading session on Feb 26.
Quarter in Detail
Adjusted earnings of $2.26 per share tumbled 9.6% year over year, though it came ahead of the Zacks Consensus Estimate of $2.03. Smucker, which belongs to the Food – Miscellaneous industry, has lost 6.5% in the past three months.
The J. M. Smucker Company Price, Consensus and EPS Surprise
Net sales of the company came in at $2,011.9 million, which beat the consensus mark of $1,984 million. Moreover, the top line increased nearly 6% year over year, mainly driven by the Ainsworth buyout and gains from the company’s growth brands. Notably, the Ainsworth acquisition contributed $199.2 million during the quarter. These upsides were partially offset by impacts from non-comparable net sales in the year-ago quarter, stemming from the divestiture of the U.S. baking business.
Excluding items that impact comparability, the top line rose 1% due to favorable volume/mix. Net price realization remained neutral in the quarter.
Adjusted gross profit jumped 6.2% to $776.7 million and adjusted gross margin expanded 20 basis points (bps) to 38.6%. Adjusted operating income climbed 1.3% to $406.2 million, though the adjusted operating margin contracted 90 bps to 20.2%.
Segment Performance
U.S. Retail Coffee Market: The company's U.S. Retail Coffee Market segment sales came in at $561.6 million, which grew 2% from the prior-year quarter’s figure. This was backed by favorable volume/mix, stemming from brands such as 1850 and Dunkin' Donuts. This was somewhat countered by reduced net price realization.
Profit in the segment rose 1% to $183.7 million thanks to improved volume/mix and lower input costs. These compensated for escalated marketing costs and reduced net price realization.
U.S. Retail Consumer Foods: Sales in the segment declined 17% to $422.7 million, largely bearing the brunt of the divestiture of the baking business. On excluding the noncomparable results, sales in the segment went up by 4%, courtesy of improved volume/mix.
Profit in the segment plunged 21% to $95.9 million, mainly due to the divestiture of the U.S. baking business. Excluding this, profit dropped 6% on account of elevated input costs, increased marketing costs and costs associated with the making of Smucker's Uncrustables production facility.
U.S. Retail Pet Foods: Net sales surged 35% to $759 million, owing to contributions from the Ainsworth buyout. Excluding the impacts from this buyout, sales in the segment went down, owing to discontinuation of Gravy Train products. Volume/mix remained unfavorable, whereas pricing improved at the segment.
Segment profit jumped 26% to $147.9 million, supported by gains from Ainsworth. Excluding this buyout, profit in the segment remained flat as increased costs were negated by greater pricing.
International and Away from Home: Net sales fell 6% from the prior-year quarter’s figure to $268.6 million, owing to lower net price realization, currency headwinds, adverse volume/mix and impacts from the divestiture of the U.S. baking business. Segment profit dipped 2% to $52.5 million, owing to lower sales, currency woes and impacts from U.S. baking business sale, somewhat made up by lower marketing expenses, and benefits from reduced pricing and costs.
Financials
Smucker exited the quarter with cash and cash equivalents of $206.5 million, long-term debt (less current portion) of $5,285.8 million and total shareholders’ equity of $8,021.6 million. Cash flow from operations amounted to $421.1 million in the quarter and free cash flow totaled $333 million.
Fiscal 2019 Outlook
Management remained pleased with the progress of its customer-focused strategy. Further, the company’s core brands like Smucker's Uncrustables, Nature's Recipe and Sahale Snacks, among others, delivered solid sales growth in the quarter. These factors along with effective cost-containment measures and efforts to keep pace with consumers evolving preferences bode well for this Zacks Rank #3 (Hold) company.
The company reiterated its outlook for fiscal 2019. Accordingly, the company expects net sales for fiscal 2019 to be $7.9 billion.
Additionally, free cash flow is still projected in the range of $700-$750 million and capital expenditures are continued to be projected in the range of $350-$370 million in fiscal 2019.
Nomad Foods (NOMD - Free Report) has long-term EPS growth rate of 11% and a Zacks Rank #2.
General Mills (GIS - Free Report) , a Zacks Rank #2 stock, has long-term EPS growth rate of 7.3%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Smucker (SJM) Stock Gains 7% on Q3 Earnings & Sales Beat
The J. M. Smucker Company (SJM - Free Report) reported third-quarter fiscal 2019 results, wherein both top and bottom lines beat the Zacks Consensus Estimate and the former improved year over year. Moreover, management reiterated its earnings outlook range, whose mid-point stands above the current consensus mark.
Markedly, the company envisions fiscal 2019 adjusted earnings per share (EPS) in the range of $8.00-$8.20, whose mid-point of $8.10 is well above the current Zacks Consensus Estimate of $8.02. These factors seem to have spurred investors’ optimism in the stock, which gained almost 7% during the pre-market trading session on Feb 26.
Quarter in Detail
Adjusted earnings of $2.26 per share tumbled 9.6% year over year, though it came ahead of the Zacks Consensus Estimate of $2.03. Smucker, which belongs to the Food – Miscellaneous industry, has lost 6.5% in the past three months.
The J. M. Smucker Company Price, Consensus and EPS Surprise
The J. M. Smucker Company Price, Consensus and EPS Surprise | The J. M. Smucker Company Quote
Net sales of the company came in at $2,011.9 million, which beat the consensus mark of $1,984 million. Moreover, the top line increased nearly 6% year over year, mainly driven by the Ainsworth buyout and gains from the company’s growth brands. Notably, the Ainsworth acquisition contributed $199.2 million during the quarter. These upsides were partially offset by impacts from non-comparable net sales in the year-ago quarter, stemming from the divestiture of the U.S. baking business.
Excluding items that impact comparability, the top line rose 1% due to favorable volume/mix. Net price realization remained neutral in the quarter.
Adjusted gross profit jumped 6.2% to $776.7 million and adjusted gross margin expanded 20 basis points (bps) to 38.6%. Adjusted operating income climbed 1.3% to $406.2 million, though the adjusted operating margin contracted 90 bps to 20.2%.
Segment Performance
U.S. Retail Coffee Market: The company's U.S. Retail Coffee Market segment sales came in at $561.6 million, which grew 2% from the prior-year quarter’s figure. This was backed by favorable volume/mix, stemming from brands such as 1850 and Dunkin' Donuts. This was somewhat countered by reduced net price realization.
Profit in the segment rose 1% to $183.7 million thanks to improved volume/mix and lower input costs. These compensated for escalated marketing costs and reduced net price realization.
U.S. Retail Consumer Foods: Sales in the segment declined 17% to $422.7 million, largely bearing the brunt of the divestiture of the baking business. On excluding the noncomparable results, sales in the segment went up by 4%, courtesy of improved volume/mix.
Profit in the segment plunged 21% to $95.9 million, mainly due to the divestiture of the U.S. baking business. Excluding this, profit dropped 6% on account of elevated input costs, increased marketing costs and costs associated with the making of Smucker's Uncrustables production facility.
U.S. Retail Pet Foods: Net sales surged 35% to $759 million, owing to contributions from the Ainsworth buyout. Excluding the impacts from this buyout, sales in the segment went down, owing to discontinuation of Gravy Train products. Volume/mix remained unfavorable, whereas pricing improved at the segment.
Segment profit jumped 26% to $147.9 million, supported by gains from Ainsworth. Excluding this buyout, profit in the segment remained flat as increased costs were negated by greater pricing.
International and Away from Home: Net sales fell 6% from the prior-year quarter’s figure to $268.6 million, owing to lower net price realization, currency headwinds, adverse volume/mix and impacts from the divestiture of the U.S. baking business. Segment profit dipped 2% to $52.5 million, owing to lower sales, currency woes and impacts from U.S. baking business sale, somewhat made up by lower marketing expenses, and benefits from reduced pricing and costs.
Financials
Smucker exited the quarter with cash and cash equivalents of $206.5 million, long-term debt (less current portion) of $5,285.8 million and total shareholders’ equity of $8,021.6 million. Cash flow from operations amounted to $421.1 million in the quarter and free cash flow totaled $333 million.
Fiscal 2019 Outlook
Management remained pleased with the progress of its customer-focused strategy. Further, the company’s core brands like Smucker's Uncrustables, Nature's Recipe and Sahale Snacks, among others, delivered solid sales growth in the quarter. These factors along with effective cost-containment measures and efforts to keep pace with consumers evolving preferences bode well for this Zacks Rank #3 (Hold) company.
The company reiterated its outlook for fiscal 2019. Accordingly, the company expects net sales for fiscal 2019 to be $7.9 billion.
Additionally, free cash flow is still projected in the range of $700-$750 million and capital expenditures are continued to be projected in the range of $350-$370 million in fiscal 2019.
Don’t Miss These Solid Food Stocks
Lamb Weston (LW - Free Report) , with long-term EPS growth rate of 12%, flaunts a Zacks Rank #2 (Buy), currently. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Nomad Foods (NOMD - Free Report) has long-term EPS growth rate of 11% and a Zacks Rank #2.
General Mills (GIS - Free Report) , a Zacks Rank #2 stock, has long-term EPS growth rate of 7.3%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>